New combo attack on HPV throat cancer: can we boost the immune system to fight tumors?
NCT ID NCT03799445
Summary
This study is testing a new combination treatment for people with a specific type of advanced throat cancer caused by HPV. It combines two immunotherapy drugs (nivolumab and ipilimumab) that help the body's immune system fight cancer, along with a targeted, lower-dose radiation therapy. The main goals are to see if this approach is safe, can shrink or eliminate the cancer, and keep it from coming back for at least two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE I HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.